Objectives: Biofilm production in extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae provides a favourable environment for the exchange of antibiotic-resistance genes and could facilitate widespread dissemination. We aimed to assess biofilm development in ESBL-producing E. coli and K. pneumoniae isolates and determine how development relates to microbiological characteristics and clinical outcomes.
INTRODUCTION
Bacteria are planktonic or exist as aggregates of cells, the latter of which is referred to as biofilm.
Biofilms are heterogeneous structures consisting of bacterial populations in an extra-cellular matrix, are present in the environment, and have the capacity to colonize diverse surfaces (Donlan and Costerton, 2002) . Bacteria with biofilms have certain advantages when compared to planktonic bacteria: increased interspecific metabolic cooperation (Shapiro, 1998) , quorum-sensing (De Araujo et al., 2010) , increased tolerance to host immune responses, requiring higher concentrations of antibiotic agents (Ceri et al., 1999) , and increased capacity for bacterial conjugation (Björklöf et al., 2000; Hennequin et al., 2012) .
In parallel, the prevalence of multi-resistant Enterobacteriaceae, namely strains able to produce extended spectrum β-lactamase (ESBL), have been drastically increasing over the past decade and thus have become a worldwide public health concern (Boucher et al., 2009) . Their spread depends on bacterial conjugation whereby plasmids carrying ESBL genes are transferred. The proximity of bacteria in biofilms creates a favourable environment for the exchange of genetic material, especially by conjugative transfer (Björklöf et al., 2000) . Coupled with the heightened survival of bacteria in biofilm, its formation might be an important factor explaining widespread distribution of multiresistant plasmids, such as CTX-M.
The two most notable Enterobacteriaceae with increasing prevalence of antibiotic resistance are Escherichia coli and Klebsiella pneumoniae. E. coli is responsible for 130-175 million urinary tract infections worldwide and 127,500 cases of sepsis in the United States each year, resulting in high rates of morbidity and mortality and extensive burden in health care costs (Russo and Johnson, 2003) . K. pneumoniae is the third most prevalent cause of bacteraemia associated with Gramnegative bacillus in France (www.onerba.fr). Since it was one of the first microorganisms to develop resistance to aminosides (Christensen and Korner, 1972) , it has played a central role in the spread of antibiotic resistance. K. pneumoniae has also gained particular notoriety with the emergence of hypervirulent strains including multiresistant ones (Turton et al., 2018 , Paczosa and Mecsas, 2016 , Surgers et al., 2016 . Despite the major therapeutic and clinical concerns with these microorganisms, few studies have examined their ability to produce biofilm and hence their potential for further dissemination.
The objective of the study herein was to determine the host and bacterial factors associated with biofilm in ESBL-producing E. coli and K. pneumoniae isolates from a large university hospital. We also intended to quantify the kinetic profiles of biofilm development, including its determinants, within these microorganisms.
MATERIALS AND METHODS

Study design and patients
Isolates were obtained from 213 patients enrolled in a cross-sectional study with the aim of determining the epidemiological characteristics of ESBL-producing Enterobacteriaceae at a single university teaching hospital (Saint-Antoine Hospital, Paris, France) from April 2012 to April 2013 (Surgers et al., 2017) . Patients presenting with an ESBL-positive sample were identified and their samples were further tested for biofilm formation.
Characteristics of the study population and isolates have been summarized in a previous publication (Surgers et al., 2017) . In brief, roughly half of patients were female (53.6%) and median age was 70 years (IQR=56-85). At least one comorbidity was present in 134 (62.9%) patients and 159 (74.7%) had at-risk exposure for ESBL carrier status (i.e., antibiotic therapy, previous hospitalization, or travel abroad) 3 months prior to infection. Of these patients, 229 strains including 147 E. coli et 82 K. pneumoniae were isolated from the following samples: urine (n=150; n=105 E. coli and n=45 K. pneumoniae), pus (n=39; n=21 E. coli and n=18 K. pneumoniae), blood culture (n=21; n=14 E. coli and n=7 K. pneumoniae), broncho-alveolar lavage (n=15; n=6 E. coli and n=9 K. pneumoniae), and from an intra-vascular device (n=4; n=1 E. coli and n=3 K. pneumoniae).
Assessing clinical characteristics
A patient was defined as "infected" if their referent physician decided to treat with antibiotics or as "colonization" otherwise. Portal of entry was classified as lung, urinary tract, digestive tract, or unknown according to the referent physician. Acquisition of ESBL-producing Enterobacteriaceae was characterized as follows: hospital-acquired, if the first positive sample was detected >48 hours (h) after admission; healthcare-associated, if the first positive sample was detected ≤48h after admission and the patient underwent hospitalization within 3 months prior; or community-acquired, if the first positive sample was detected ≤48h of admission without any recent hospitalization. Data on transfer to the intensive care unit (ICU) and all-cause deaths within 12 months after entry into care were obtained from electronic patient medical records. Only "infected" patients had available data on ICU transfer.
Genotyping of strains
Data on bacterial characterization were obtained as previously described (Surgers et al., 2017) .
Different multiplex PCR systems were used to determine β-lactamase genes (Dallenne et al., 2010) , phylogenetic groups for E. coli (Clermont et al., 2013) , multilocus sequence typing (MLST) for K. pneumoniae (Diancourt et al., 2005) , as well as plasmids carrying resistance ESBL genes Caratolli et al., 2005) . Using a PCR-based method, strains of E. coli were screened for 12 genes encoding putative virulence factors, which included adhesins [ibeA putative invasion, sfa/foc S or F1 C fimbriae, papC genes of P fimbrial operon, papG (II and III alleles), flu and Dr-binding draBC], toxins (hlyC hemolysin and cnf1 cytotoxic necrotizing factor) and iron capture systems (iucC, fyuA iron uptake, iroN, salmochelin receptor) (Bonacorsi et al., 2006; Ulett et al., 2007; Johnson and Stell, 2000) . For K. pneumoniae, genes encoding seven separate virulence factors were detected using multiplex PCR: allS, rmpA, type 3 fimbriae (mrKD), siderophores (entB, kfu, ybtS, iutA) and the two capsular serotypes K1 (magA) and K2 (wzi) .
Assessing biofilm formation
Biofilm formation was assessed by a microbead immobilization assay [BioFilm Ring test® (BRT), Biofilm control, St Beauzire, France] as previously described (Chavant et al., 2007; Olivares et al., 2016) . The BRT offers a reproducible and quantifiable measure of biofilm production and has shown strong correlation with crystal violet staining (Crémet et al., 2013) . Since this assay is automated, any non-standardized washing or staining techniques are removed. Briefly, microorganisms were cultured overnight in blood heart infusion (BHI). Medium standardized bacterial cultures were incubated at 37°C in 96-well microtiter plates with magnetic beads. After different times of incubation (1h30min, 4h, 6h, 24h), microplates were placed onto a magnetic block and read by a BRT device. For each experiment, we used a positive control (strong biofilm producer strain, personal collection) and two negative controls (one without any strains and the other with a strain incapable of producing biofilm after multiple BRT runs). The plates were analysed using the Biofilm Control software, which gives a quantitative Biofilm Formation Index (BFI) ranging from 0 to 21. Higher BFI values correspond to high mobility of beads under magnetic action due to lack of biofilm, while lower values correspond to full immobilization of beads due to the presence of biofilm. Each strain was tested in two independent experiments and the average of the two experiments was used as the final BFI value.
Statistical analysis
Unless otherwise stated, all comparisons were made using Kruskal-Wallis rank test for continuous variables and Pearson's χ² or Fisher's Exact test for categorical variables. All analysis was carried out by STATA statistical software (v12.1, College Station, TX, USA) and a p-value <0.05 was considered significant.
Initially, we modelled the kinetics of the BFI during the first 6h of incubation. If isolates were able to achieve levels <2 prior to 6h, they were assumed to have maintained this level until the 6h timepoint. Change from baseline BFI was modelled over incubation time using mixed-effect linear regression in which a random-intercept was incorporated to account for within-isolate variability.
Average BFI levels and their 95% confidence intervals (CI) were directly calculated from this model using the delta-method. In order to test overall differences in kinetics between factor levels, the interaction between factor and interval time was tested while including its individual effects.
In subsequent analysis, biofilm production was represented as follows: (i) presence or absence of standard biofilm defined as achieving a level <7 or ≥7 within 24h, respectively; and (ii) rapid, slow, and no standard biofilm development defined as achieving a cut-off <7 within ≤4h, >4 h, and never, respectively. We based this cut-off on the distribution of BFI values at the last time point (median levels), which also corresponded to group-trajectory projections from preliminary analysis.
Nevertheless, it should be noted that lack of biofilm production is generally considered at a BFI >18 and no standardized cut-off is recommended for confirmation of biofilm production. In order to understand the role of bacterial or clinical determinants on biofilm production, both biofilm endpoints were examined in a two-part, univariable analysis. First, genetic characteristics were compared between biofilm production groups while stratified on either E. coli or K. pneumoniae species. Second, host factors and outcomes observed during/after infection were compared between biofilm production groups for all isolates.
RESULTS
Genetic characteristics of ESBL-producing strains
Among the 147 E. coli isolates, the most common ESBL sequence was CTX-M-15 (n=65, 44.2%), followed by CTX-M-14 (n=34, 23.1%) and CTX-M-1 (n=21, 14.3%). Virulent phylogenetic groups constituted 60.5% of E. coli isolates (B2, n=74; D, n=15), while all others were less virulent (A, n=21; B1, n=12; C, n=12; E, n=7; F, n=6). Of the 82 (35.8%) K. pneumoniae isolates, the large majority produced CTX-M-15 (n=74, 90.2%), with much lower prevalence of CTX-M-14 (n=5, 6.1%) and CTX-M-1 (n=2, 2.4%). A wide range of MLST types were identified, while some ST types were more frequently observed: ST29, n=19 (23.2%); ST147, n=11 (13.4%); ST323, n=16 (19.5%); and ST405, n=5 (6.1%). Only 4 (4.9%) strains were identified with K2 and none with K1 capsular genes.
Kinetics of biofilm production during incubation
The average difference (±standard deviation) between the two BFI measures within isolates was constant over time: 1.0±0.1 at 1.5h, 1.2±0.1 at 4h, and 1.2±0.1 at 6h. Overall, average BFI levels dropped from 21 to 18.9 (95%CI=18.1-19.6) at 1.5h, .2) at 4h, and finally to 6.2 (95%CI=5.4-6.9) at 6h ( Figure 1A ) of incubation. The rate of BFI decline was significantly faster for K.
pneumoniae than E. coli (p<0.001), particularly at 4h and 6h ( Figure 1B ).
Faster unadjusted kinetics were also identified for the following characteristics: overall -source of episode (in three groups: nosocomial, health-care associated, community acquired; p<0.001); E. colitoxin (p<0.001) or adhesin (p=0.003) virulence factors; K. pneumoniae MLST type (p=0.045) (Supplementary Table 1 ).
The distribution of BFI levels at each time-point of incubation is given in Figure 1C . Almost one-third of strains had a BFI level <2 at 4h. Most strains were able to strongly produce biofilm with a BFI <2 (57.1%) by the end of 24h, while a minority did not indicate any biofilm production (BFI >18, 13.4%).
A significantly higher proportion of K. pneumoniae strains produced BFI levels <2 within 24h compared to E. coli (78.1% versus 45.6%, p<0.001).
Bacteriological and clinical determinants of biofilm development
For E. coli bacteria (Table 1) , biofilm development was significantly less likely to be observed in ST131 strains and those with the fyuA virulence factor (p=0.03 and p=0.01, respectively), whereas it was more likely for strains with hly and papC virulence factors (p=0.009 and p=0.006, respectively). In particular, rapid biofilm development was observed more frequently in strains with toxin (hly, p=0.009; cnf1, p=0.04) and adhesin (papC, p=0.005; papGIII, p=0.04; papGII, p=0.05 ) virulence factors (Table 1) . Any multivariable analysis was precluded by the high collinearity between these genetic components. Nevertheless, the virulence factors less likely to be observed on non-ST131 versus ST131 strains, respectively, were fyuA (0% vs 49.1%, p<0.001) and papGII (30.2% vs 66.6%, p=0.002), which indicates some grouping in these genetic factors with respect to biofilm formation. There were no genetic determinants for K. pneumoniae bacteria (Table 2) , likely owing to the few strains unable to produce biofilm (n=8, 9.8%).
The frequency of biofilm development between various clinical factors is given for all isolates in Table   3 . There was a significant difference in biofilm development between specific sources of infection (nosocomial versus health-care associated/community-acquired) (p=0.048). Infections observed in urine were less likely to exhibit biofilm development (p=0.008), while the opposite was true for digestive tract infections (p=0.006). The proportion harbouring biofilm-producing strains was not significantly different between patients with colonized versus treated/palliative infection (p=0.5).
Serious clinical outcomes and biofilm development
In the 99 patients with established infection, 16/18 of patients (88.9%) transferred to the ICU had biofilm producing isolates versus 60/81 of patients (74.1%) who were not. This difference was not significant (p=0.2), even when stratifying on E. coli (p=0.3) or K. pneumoniae (p=0.9) isolates. If we assume that all colonized individuals were not admitted to the ICU, 88.9% (n=2/18) and 70.9% (n=59/144) transferred and non-transferred patients, respectively, had strains with biofilm (p=0.17).
There was a slight trend in increasing ICU transfer rates with increasing rate of biofilm development:
none, n=2/23 (8.7%); slow, n=3/17 (17.7%); fast, n=13/59 (22.0%) (τb=0.13); however, this was not significant (p for non-parametric trend=0.17).
In the 158 patients with data on all-cause mortality, 13/66 of patients (80.3%) who died had strains with biofilm, compared to 66/92 of patients (71.7%) who remained alive (p=0.2). These proportions were, respectively, 68.4% and 63.6% for E. coli (p=0.6) and 96.4% and 83.8% for K. pneumoniae (p=0.13). There were no significant differences in biofilm presence between dead versus alive patients, respectively, with colonization (88.0% versus 71.7%, p=0.16) or infection (71.9% versus 75.6%, p=0.7). There was again a slight trend in increasing death with higher rates of biofilm development: none, n=13/39 (33.3%); slow, n=12/32 (37.5%); fast, n=41/87 (47.1%) (τb=0.12); yet was not significant (p for non-parametric trend=0.13).
DISCUSSION
Biofilm production provides an important pathogenic advantage, allowing protection against host immune responses and reduced susceptibility to antibiotic therapy (Donlan and Costerton, 2002) . In this large collection of strains obtained from a single centre, we noticed that biofilm was produced in roughly three-quarters of isolates, demonstrating the troubling extent of this problem in ESBLproducing microorganisms. Furthermore, biofilm was significantly more prevalent in K. pneumoniae than E. coli species and in digestive tract infections. The extensive genetic characterization of these strains has helped further our understanding of the more common circumstances under which biofilm can be observed.
Interestingly, we found a close relationship with several different virulence factors and the capacity to produce biofilm. Biofilm was much less common among E. coli isolates with siderophore virulence factors, with the strongest difference observed in iucC. In contrast, a previous study by Hancock et al. (2008) found that the siderophore virulence factor fyuA was required for efficient biofilm formation in E. coli, but by itself does not account for increased biofilm production. Nevertheless, their study only included urinary tract infections and hence the discrepancy with our study might also be due to infection location. Isolates harbouring fyuA require biofilm production in iron-poor environments, such as urine, whereas it might not be necessary in other sites.
In contrast, the presence of toxin or adhesin virulence factors was significantly associated with increased biofilm production. Furthermore, the toxin hly and cnf1 virulence factors, as well as adhesin papC, papGIII, and to some extent papGII factors, were associated with rapid development of biofilm, as defined by our assay. Our findings support the predominant role of these virulence factors in biofilm production, consistently observed across E. coli isolates from various settings with differing genetic characteristics (i.e. non-ESBL, colonization, lacking antimicrobial resistance genes, etc.) (Naves et al., 2008) . The hly virulence factor has also been implicated in biofilm development during prostatitis due to E. coli infection (Soto et al., 2007) . Given that simultaneous biofilm production across certain virulence factors tends to cluster in pathogenicity islands, which at times results in increased virulence, their prevalence is fairly concerning.
Other genetic factors have been certainly implicated in biofilm production. Clermont et al. described biofilm in CTX-M-15 producing E. coli ST131 that was not contained within the CTX-M plasmid (Clermont et al., 2008) . In another study, the prevalence of biofilm production was significantly higher among ST131 than non-ST131 isolates regardless ESBL-production and antibiotic resistance (Kudinha et al., 2013) . More refined analysis from Pantel et al. has demonstrated largely diverse biofilm activity in E. coli ST131 clones (Pantel et al., 2016) , as substantiated by others (Olesen et al., 2014; Shin and Ko., 2015) . In this study, we also observed a strong relationship between ST131 strains and two virulence factors, fyuA and papGII, both of which, when absent, are significantly associated with biofilm production. Perhaps the variability of ST131 subclones or types of concomitant virulence factors in our cohort could explain why an inverse association was observed between ST131 and biofilm production.
With regards to K. pneumoniae, the pervasiveness of biofilm in ESBL-producing strains has been demonstrated in a previous study (Yang and Zhang, 2008) . Type 3 fimbriae are known to serve as appendages mediating the formation of biofilm and are a major determinant of fimbrial binding specificity (Murphy CN, Clegg S, 2012) . As all isolates in this study were ESBL-producing and 98.8% of K. pneumoniae had mrkD, a protein located at the tip of the type 3 fimbriae; it is unsurprising that this bacterial species was able to produce biofilm at such a large extent. Inasmuch as we could determine, biofilm development was more frequent in the widespread K. pneumoniae types ST29, ST147, and ST323; while data from biofilm kinetics demonstrated a significantly faster rate of biofilm production in these clones compared to others. How these results relate to the dissemination of K. pneumoniae would need further investigation.
One of the more novel aspects of this study was the evaluation of biofilm kinetics during incubation, permitting us to distinguish isolates with rapid versus slow biofilm production. With E. coli in particular, isolates with slow biofilm development rarely had characteristics that are classically identified as "pathogenic" (i.e.CTX-M-15, ST131, or the virulent phylogenetic groups B2/D). Rather, the more "pathogenic" bacteria exhibited a bimodal pattern of either rapid or no biofilm development. In contrast, K. pneumoniae isolates had much faster kinetics of biofilm production compared to E. coli, especially within 4-6h of incubation, resulting in the vast majority of K. pneumoniae bacteria reaching BFI <2 within 24h.
We did not notice any relationship between biofilm-producing isolates and ICU transfers or deaths within 12-months. However, the high overall mortality rate due to a study population with multiple co-morbidities and lack of sample size might have restricted our capacity to determine a statistically significant difference. To our knowledge, there are conflicting reports on how biofilm production could serve as an underlying cause of morbidity and mortality. Other extrinsic factors are likely implicated. For example, biofilm-producing bacteria are often found on foreign objects (i.e. urinary catheters, intra-vascular devices, etc.), could be cleared when these objects are removed, and thus provide limited effect on clinical outcomes (Guembe M et al., 2017) . Conversely, biofilm formation appears to play a role in recurrence of some infections, making them difficult to clear (Soto et al., 2006) , and are particularly difficult to treat (Hoiby et al., 2015) . These factors could confound its direct association with mortality. Larger datasets would be needed to clearly establish the relationship with biofilm and more severe clinical outcomes in patients infected with ESBL-producing microorganisms.
Other limitations of our study should be acknowledged. First, there are a variety of techniques available to study biofilm development in vitro (Lebeaux et al., 2013 ), yet these methods have not been standardized. Biofilm production also varies under certain experimental conditions (i.e. presence of oxygen, culture mediums, etc.) (Hancock et al., 2011; Naves et al., 2008) , further complicating between-assay comparisons. Nevertheless, we opted to use a novel method based on the immobilization of magnetic beads by bacteria when biofilm is secreted, which was able to reduce the number of non-standardized steps (Chavant et al., 2007) and has shown strong correlation with the crystal violet method (Crémet et al., 2013) . This method has also demonstrated higher sensitivity in detecting biofilm in the early phases of production (Chavant et al., 2007; Lebeaux et al., 2013) , making it particularly useful to study its kinetics. Second, considering that there is no official definition for biofilm production with the BRT device, we used a cut-off derived from our study isolates at an index level of 7. Clearer definitions of more biologically and clinically meaningful values of the BFI need to be established. Third, we were unable to characterize plasmids carrying antimicrobial resistance for roughly half of all strains. The link between resistance genes and biofilm production was not assessed due to the lack of available data. Fourth, we did not test for all known virulence factors. Finally, although we present results from a wide range of clinical settings, the increased heterogeneity might have impacted our ability to characterize phenomenon specific to infection site. Studies with greater numbers of isolates would be more adequate in addressing these questions.
In conclusion, biofilm production was more common in ESBL-producing E. coli harbouring adhesin and toxin virulence factors, while it was extensively present across most K. pneumoniae ESBLproducing isolates. Since there was a slight trend in increasing mortality with more rapid biofilm development, further exploration on the clinical value of biofilm kinetics should be conducted in larger collections of isolates. Further understanding of biofilm kinetics and development could be improved by comparing these isolates to non-ESBL-producing or wildtype E. coli and K. pneumoniae infections within similar settings.
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